Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR-hTNF plus Anthracycline in Platinum-resistant Ovarian Cancer
NCT01358071Phase 2Completed
- Sponsor
- AGC Biologics
- Start
- Jun 2011
- Primary completion
- Dec 2016
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of NGR-TNF in ovarian cancer (2 arms), sponsored by AGC Biologics. Primary endpoint: Progression-Free Survival. Started Jun 2011; status: completed.
02
Drugs
NGR-TNF
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT01358071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01358071.